Dr. Motzer on the TIVO-1 Trial With Tivozanib in Advanced RCC

Publication
Video
Supplements and Featured PublicationsUpdates in Relapsed/Refractory Metastatic Renal Cell Carcinoma: An OncLive® Scientific Interchange and Workshop
Volume 1
Issue 1

In Partnership With:

Robert J. Motzer, MD, discusses the phase 3 TIVO-1 trial comparing tivozanib with sorafenib in patients with advanced renal cell carcinoma.

Robert J. Motzer, MD, Kidney Cancer section head, genitourinary oncology service and Jack and Dorothy Byrne chair in Clinical Oncology with Memorial Sloan Kettering Cancer Center, discusses the phase 3 TIVO-1 trial comparing tivozanib (Fotivda) with sorafenib (Nexavar) in patients with advanced renal cell carcinoma.

Tivozanib is a highly selective and potent VEGF inhibitor. The agent was evaluated in the large TIVO-1 trial, where it was compared with sorafenib, says Motzer. The TIVO-1 trial reached its primary end point by showing improvement in progression-free survival with tivozanib, although an overall survival benefit was not observed. Additionally, because of the design of the trial, the survival favored sorafenib over tivozanib, explains Motzer.

Tivozanib has remained an investigational agent in the United States, says Motzer. The agent has been approved for use in Europe in select circumstances, concludes Motzer.

Related Videos
Sarah E. S. Leary, MD, MS, attending physician, medical director, Pediatric Brain Tumor Program, Seattle Children’s Hospital; professor, Department of Pediatrics, University of Washington School of Medicine
Rita Nanda, MD
Vikram Narayan, MD
Daniel Olson, MD
Vishal Patel, MD, FAAD, FACMS, associate professor, Dermatology, George Washington (GW) School of Medicine & Health Sciences
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute